Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11825332 | 1.00 | CYP2C19 (0.32) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL11815232 | 0.91 | — | — | |
| SCHEMBL1880025 | 0.84 | — | — | |
| SCHEMBL1477910 | 0.77 | CYP2C19 (0.42) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL1421 | 0.77 | CYP2C19 (0.42) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL6917016 | 0.74 | CYP2C19 (0.41) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL6917012 | 0.74 | CYP2C19 (0.41) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL6914957 | 0.74 | CYP2C19 (0.41) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL1999275 | 0.74 | TSHR (0.33) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL6913628 | 0.74 | CYP2C19 (0.41) | CYP2C19USP2ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110234635-A | Novel substituted benzimidazole derivatives as D-amino oxidase (DAAO) inhibitors | 宇凤·简·曾 | 2019-09-13 | — | — | CN | disclosed |
| US-9682911-B2 | Method for producing α-halogenoacetophenon compound, and α-bromoacetophenon compound | FUJIFILM CORPORATION (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9682911-B2 | Method for producing α-halogenoacetophenon compound, and α-bromoacetophenon compound | FUJIFILM CORPORATION (JP) | 2017-06-20 | — | — | US | disclosed |
| EP-3053908-A1 | METHOD FOR PRODUCING alpha-HALOGENOACETOPHENON COMPOUND, AND alpha-BROMOACETOPHENON COMPOUND | FUJIFILM Corporation (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-20160200654-A1 | METHOD FOR PRODUCING ALPHA-HALOGENOACETOPHENON COMPOUND, AND ALPHA-BROMOACETOPHENON COMPOUND | FUJIFILM CORPORATION (JP) | 2016-07-14 | — | — | US | disclosed |
| US-20160200654-A1 | METHOD FOR PRODUCING ALPHA-HALOGENOACETOPHENON COMPOUND, AND ALPHA-BROMOACETOPHENON COMPOUND | FUJIFILM CORPORATION (JP) | 2016-07-14 | — | — | US | disclosed |
| EP-1857471-B1 | POLYMERIZATION CATALYST COMPOSITION AND PROCESS FOR PRODUCTION OF POLYMER | MITSUI CHEMICALS INC (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-7960305-B2 | a mixture of a phosphazenium compound such as tetrakis[tris(dimethylamino)phosphoranylideneamino]phosphonium chloride, transition metal halides and an organic halogen compound as an activator, used for addition homo/copolymerization; living polymers | MITSUI CHEMICALS, INC. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20080177014-A1 | Polymerization Catalyst Composition and Process for Production of Polymer | MITSUI CHEMICALS, INC. (JP) | 2008-07-24 | — | — | US | disclosed |
| EP-1857471-A1 | POLYMERIZATION CATALYST COMPOSITION AND PROCESS FOR PRODUCTION OF POLYMER | Mitsui Chemicals, Inc. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-3954730-A | ANTIBIOTICS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200654-A1 | METHOD FOR PRODUCING ALPHA-HALOGENOACETOPHENON COMPOUND, AND ALPHA-BROMOACETOPHENON COMPOUND | CYP2B6, CYP2A6, CA6 | CYP2C19 467/4885USP2 1735/4885ALDH1A1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.